Skip to main content

Table 3 Frequencies of inferred CYP2C8 metabolizer phenotype

From: Meta-analysis of the global distribution of clinically relevant CYP2C8 alleles and their inferred functional consequences

Country

NMs (%)

IMs (%)

PMs (%)

Africa

Tanzania

63.6/67.4

32.3/29.4

4.1/3.2

Uganda

80.2

18.7

1.1

Madagascar

72.2

25.5

2.3

Eritrea

79.8/88.4

19.1/11.2

1.1/0.4

Nigeria

65.4

30.9

3.7

Mali

70.5

26.9

2.6

Burkina-Faso

66.6/67.2

30/29.5

3.4/3.3

Senegal

60.6

34.5

4.9

Ghana

67.3

29.5

3.2

Botswana

79

19.8

1.2

Mozambique

61.5/69.4

33.8/27.8

4.7/2.8

South Africa and Zimbabwe

71.4

26.2

2.4

Gabon

67.8

29.1

3.1

Congo

39.9

46.5

13.6

Americas

Mexico

75.8/89.4

22.5/10.3

1.7/0.3

USA

77.1/90.7

21.4/9.1

1.5/0.2

Ecuador

84.4/100

14.9/0

0.7/0

Brazil

68.2/83.1

28.8/16.1

3/0.8

Bolivia

92.4/100

7.5/0

0.1/0

Europe

Denmark

81.2/100

17.8/0

1/0

Norway

82.7/100

16.5/0

0.8/0

Sweden

70.6/88

26.8/11.6

2.6/0.4

Faroese Island

86.7/100

12.8/0

0.5/0

Finland

69.6/88.5

27.7/11.1

2.7/0.4

UK

72.8/84.6

25/14.8

2.2/0.6

Scotland

72.1/100

25.6/0

2.3/0

Italy

79.9/100

19/0

1.1/0

Spain

60.2/87.1

34.8/12.4

5/0.5

Portugal

52.7/85.3

39.8/14.1

7.5/0.6

Russia

83.4/100

15.8/0

0.8/0

Czech Republic

68.7/88

28.4/11.6

2.9/0.4

Bulgaria

78.8/100

19.9/0

1.3/0

Hungary

76.1/92.3

22.3/7.6

1.6/0.1

Germany

80.9/100

18.1/0

1/0

Netherlands

73/90.9

24.9/8.9

2.1/0.2

Asia

Malaysia

89/92.6

10.7/7.3

0.3/0.1

Cambodia

100

0

0

China

93.9/97.7

6/2.3

0.1/0

Japan

98.4

1.6

 < 0.1

Korea

98

2

 < 0.1

India

86/91.7

13.5/8.1

0.5/0.2

Jordan

79.3/87.2

19.5/12.4

1.2/0.4

Oceania

Australia

76.4/92.5

22/7.3

1.6/0.2

  1. The percentages of the different metabolizer phenotypes are shown for amodiaquine (before the “/”), where CYP2C8*3 is considered a reduced function allele, and for other substrates (after the “/”), where CYP2C8*3 is associated with normal function
  2. NM Normal metabolizers; IM Intermediate metabolizers; PM Poor metabolizers